Cancer Rates in Patients Treated with Glucagon-Like Peptide-1 Receptor Agonists
By
Zayed Rashid
Selamawit Woldesenbet
Mujtaba Khalil
Abdullah Altaf
Shahzaib Zindani
Areesh Mevawalla
Azza Sarfraz
Khalid Mumtaz
Timothy M. Pawlik
February 26, 2026
Clinical Scorecard: Cancer Rates in Patients Treated with Glucagon-Like Peptide-1 Receptor Agonists
At a Glance
Category Detail
Condition Cancer incidence in patients treated with GLP-1 receptor agonists Key Mechanisms GLP-1 RAs mimic incretins, influencing insulin and glucagon secretion, and altering pathways involved in tumorigenesis. Target Population Adults aged 18-64 with type 2 diabetes mellitus (T2DM) Care Setting Outpatient and inpatient settings using a national insurance database
Key Highlights
GLP-1 RAs may lower colorectal cancer incidence in diabetes patients. Potential increased risk of thyroid cancer linked to GLP-1 RA therapy. Conflicting evidence regarding GLP-1 RAs and pancreatic cancer risk. Study utilized a large population from the IBM-MarketScan database. Focus on common thoracic, gastrointestinal, gynecological, and endocrine cancers. Guideline-Based Recommendations
Diagnosis
Utilize validated ICD codes for identifying T2DM and cancer diagnoses. Management
Consider GLP-1 RAs for managing diabetes and obesity while monitoring cancer risk. Monitoring & Follow-up
Follow patients for cancer incidence post GLP-1 RA initiation. Risks
Assess individual patient risk factors for thyroid and pancreatic cancer. Patient & Prescribing Data
Individuals aged 18-64 diagnosed with T2DM.
GLP-1 RAs are associated with metabolic benefits but require careful monitoring for potential cancer risks.
Clinical Best Practices
Ensure continuous enrollment in insurance plans for accurate data tracking. Exclude patients with prior GLP-1 RA use or cancer diagnosis within specified timeframes. Related Resources & Content
